Shares of ConvaTec Group PLC (LON:CTEC – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is GBX 308.78.
Several research analysts have issued reports on CTEC shares. JPMorgan Chase & Co. dropped their target price on ConvaTec Group from GBX 307 to GBX 294 and set an “overweight” rating on the stock in a research report on Friday, May 22nd. Citigroup dropped their target price on ConvaTec Group from GBX 250 to GBX 230 and set a “neutral” rating on the stock in a research report on Monday, May 18th. Stifel Nicolaus reissued a “buy” rating and issued a GBX 315 target price on shares of ConvaTec Group in a research report on Wednesday, March 11th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 325 target price on shares of ConvaTec Group in a research report on Friday, May 15th. Finally, Berenberg Bank reissued a “buy” rating and issued a GBX 340 target price on shares of ConvaTec Group in a research report on Tuesday, April 21st.
Get Our Latest Report on ConvaTec Group
Insider Buying and Selling at ConvaTec Group
ConvaTec Group Price Performance
LON CTEC opened at GBX 194 on Tuesday. The company has a market capitalization of £3.79 billion, a price-to-earnings ratio of 22.56, a PEG ratio of 0.93 and a beta of 0.78. The company has a debt-to-equity ratio of 106.19, a quick ratio of 0.96 and a current ratio of 1.53. The stock has a 50-day moving average of GBX 216.58 and a 200 day moving average of GBX 228.95. ConvaTec Group has a one year low of GBX 193 and a one year high of GBX 311.20.
ConvaTec Group Company Profile
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
Featured Stories
- Five stocks we like better than ConvaTec Group
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Receive News & Ratings for ConvaTec Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConvaTec Group and related companies with MarketBeat.com's FREE daily email newsletter.
